Hubei Biocause Pharmaceutical Co., Ltd. (000627) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Weak Long Term Fundamental Strength as the company has not declared results in the last 6 months

Poor long term growth as Net Sales has grown by an annual rate of -2.94% and Operating profit at -174.64%

Negative results in Sep 24

Risky - Not traded in last 10 days

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals: Major

Market cap

CNY 13,537 Million (Small Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.31

Return on Equity

-6.91%

Price to Book

0.62

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2024)

Net Profit:

67 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-58.31%

6 Months

-54.47%

1 Year

-33.61%

2 Years

-54.07%

3 Years

-44.37%

4 Years

-58.64%

5 Years

-71.32%

Hubei Biocause Pharmaceutical Co., Ltd. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-2.94%

EBIT Growth (5y)

-174.64%

EBIT to Interest (avg)

44.73

Debt to EBITDA (avg)

175.86

Net Debt to Equity (avg)

0.80

Sales to Capital Employed (avg)

1.10

Tax Ratio

11.40%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

0.03%

ROE (avg)

3.29%

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.62

EV to EBIT

EV to EBITDA

481.11

EV to Capital Employed

0.71

EV to Sales

0.48

PEG Ratio

Dividend Yield

ROCE (Latest)

ROE (Latest)

-6.91%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'24 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2024 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2024 is 112.38% vs -212.95% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'24",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "66.70",
          "val2": "-538.90",
          "chgp": "112.38%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "32.40%",
          "val2": "-26.10%",
          "chgp": "5.85%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2023 is 0.00% vs 0.00% in Dec 2022",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2023 is -350.98% vs -41.99% in Dec 2022",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Dec'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "165.20",
          "val2": "166.60",
          "chgp": "-0.84%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "808.40",
          "val2": "691.00",
          "chgp": "16.99%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2,659.20",
          "val2": "-147.30",
          "chgp": "-1,705.30%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1,281.50",
          "val2": "510.60",
          "chgp": "-350.98%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "30.10%",
          "val2": "11.90%",
          "chgp": "1.82%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'24 - QoQ

Sep'24

Jun'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

0.00

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

66.70

-538.90

112.38%

Operating Profit Margin (Excl OI)

32.40%

-26.10%

5.85%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Sep 2024 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

QoQ Growth in quarter ended Sep 2024 is 112.38% vs -212.95% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'23

Dec'23

Dec'22

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

165.20

166.60

-0.84%

Interest

808.40

691.00

16.99%

Exceptional Items

-2,659.20

-147.30

-1,705.30%

Consolidate Net Profit

-1,281.50

510.60

-350.98%

Operating Profit Margin (Excl OI)

30.10%

11.90%

1.82%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2023 is 0.00% vs 0.00% in Dec 2022

Consolidated Net Profit

YoY Growth in year ended Dec 2023 is -350.98% vs -41.99% in Dec 2022

All Annual Results

Company CV

About Hubei Biocause Pharmaceutical Co., Ltd.

Hubei Biocause Pharmaceutical Co., Ltd.

Pharmaceuticals: Major

No Details Available.

Company Coordinates

No Company Details Available